Castration-resistant prostate cancer: [177Lu]Lu-PSMA-617 versus cabazitaxel Comment

被引：0
|
作者：
Todenhoefer, Tilman [1 ]
机构：
[1] Studienpraxis Urol, Steinengrabenstr 17, D-72622 Nurtingen, Germany
来源：
AKTUELLE UROLOGIE | 2023年 / 54卷 / 04期
关键词：
D O I：
10.1055/a-2084-8214
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu] Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)
    Fettke, Heidi
    Kostos, Louise
    Buteau, James
    Steen, Jason A.
    Medhurst, Elizabeth
    Haskali, Mo B.
    Murphy, Declan
    Docanto, Maria
    Bukczynska, Patricia
    Ng, Nicole
    Sandhu, Shahneen
    Foroughi, Siavash
    Furic, Luc
    Nguyen-Dumont, Tu
    Hofman, Michael S.
    Azad, Arun A.
    CANCER RESEARCH, 2023, 83 (07)
  • [32] Treatment of castration-resistant metastatic prostate cancer with [177Lu]PSMA radioligand
    Sundset, Rune
    Haugnes, Hege Sagstuen
    Perez, Alexander
    Engelsen, Ola
    Fosseide, Ida H. H.
    Castillejo, Miguel J.
    Bogsrud, Trond Velde
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2024, 144 (09)
  • [33] Safety Analyses of the Phase 3 VISION Trial of [ 177 Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
    Chi, Kim N.
    Armstrong, Andrew J.
    Krause, Bernd J.
    Herrmann, Ken
    Rahbar, Kambiz
    de Bono, Johann S.
    Adra, Nabil
    Garje, Rohan
    Michalski, Jeff M.
    Kempel, Mette M.
    Fizazi, Karim
    Morris, Michael J.
    Sartor, Oliver
    Brackman, Marcia
    Desilvio, Michelle
    Wilke, Celine
    Holder, Geoffrey
    Tagawa, Scott T.
    EUROPEAN UROLOGY, 2024, 85 (04) : 382 - 391
  • [34] PSMA and FDG PET as Predictive and Prognostic Biomarkers in Men with Metastatic, Castration-Resistant Prostate Cancer (mCRPC): an Analysis of the Randomised, Phase 2 Trial of [177Lu]Lu-PSMA-617 Versus Cabazitaxel (TheraP, ANZUP 1603)
    Buteau, J.
    Martin, A.
    Emmett, L.
    Iravani, A.
    Sandhu, S.
    Joshua, A. M.
    Francis, R. J.
    Zhang, A. Y.
    Scott, A. M.
    Lee, S.
    Azad, A.
    McJannett, M.
    Stockler, M. R.
    Williams, S.
    Davis, I. D.
    Hofman, M. S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S55 - S55
  • [35] Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.
    Tagawa, Scott T.
    Armstrong, Andrew J.
    Krause, Bernd J.
    Herrmann, Ken
    Rahbar, Kambiz
    De Bono, Johann S.
    Adra, Nabil
    Desilvio, Michelle
    Messmann, Richard
    Holder, Geoffrey
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] [177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study
    Satapathy, Swayamjeet
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Sahoo, Ranjit Kumar
    Bal, Chandrasekhar
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (08) : 2495 - 2503
  • [37] Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results
    Herrmann, Ken
    Gafita, Andrei
    De Bono, Johann S.
    Sartor, A. Oliver
    Chi, Kim N.
    Krause, Bernd J.
    Rahbar, Kambiz
    Tagawa, Scott T.
    Czernin, Johannes
    El-Haddad, Ghassan
    Wong, Connie
    Zhang, Zhaojie
    Wilke, Celine
    Mirante, Osvaldo
    Morris, Michael J.
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
    Justin Ferdinandus
    John Violet
    Shahneen Sandhu
    Rodney J. Hicks
    Aravind S. Ravi Kumar
    Amir Iravani
    Grace Kong
    Tim Akhurst
    Sue Ping Thang
    Declan G. Murphy
    Scott Williams
    Michael S. Hofman
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2322 - 2327
  • [39] Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
    Ferdinandus, Justin
    Violet, John
    Sandhu, Shahneen
    Hicks, Rodney J.
    Ravi Kumar, Aravind S.
    Iravani, Amir
    Kong, Grace
    Akhurst, Tim
    Thang, Sue Ping
    Murphy, Declan G.
    Williams, Scott
    Hofman, Michael S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (10) : 2322 - 2327
  • [40] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer reply
    Hofman, Michael S.
    Violet, John
    Hicks, Rodney J.
    Sandhu, Shahneen
    LANCET ONCOLOGY, 2018, 19 (08): : E373 - E373
12345